RecruitingPhase 3NCT05814432

Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

Studying Histoplasmosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Federal University of Health Science of Porto Alegre
Principal Investigator: Daiane F Dalla Lana, PhD
Federal University of Health Science of Porto Alegre
Intervention: Single high dose of liposomal amphotericin B(drug)
Enrollment: 279 target
Eligibility: 18 years · All sexes
Timeline: 2025 – 2026

Study locations (5)

Hospital de Doenças Tropicais, Goiânia, Goiás, Brazil
Hospital Giselda Trigueiro, Natal, Rio Grande do Norte, Brazil
Federal University of Health Sciences of Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
Hospital de Clinicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil
Hospital Geral de Roraima, Boa Vista, Roraima, Brazil

Collaborators

Gilead Sciences · Financiadora de Estudos e Projetos · Sociedade Gaucha de Infectologia · Immuno-mycologics, Inc. (IMMY)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05814432 on ClinicalTrials.gov

← Back to all trials